WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H534939
CAS#: 32828-81-2
Description: Picotamide has anticoagulant & fibrinolytic properties.
Hodoodo Cat#: H534939
Name: Picotamide
CAS#: 32828-81-2
Chemical Formula: C21H20N4O3
Exact Mass: 376.15
Molecular Weight: 376.416
Elemental Analysis: C, 67.01; H, 5.36; N, 14.88; O, 12.75
This product is not in stock, which may be available by custom synthesis.
For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge).
Quote less than 1g will not be provided. To request quote, please email to sales @hodoodo.com or click below button.
Note: Price will be listed if it is available in the future.
Synonym: Picotamide
IUPAC/Chemical Name: 1,3-Benzenedicarboxamide, N,N'-bis(3-pyridinylmethyl)-4-methoxy-
InChi Key: KYWCWBXGRWWINE-UHFFFAOYSA-N
InChi Code: InChI=1S/C21H20N4O3/c1-28-19-7-6-17(20(26)24-13-15-4-2-8-22-11-15)10-18(19)21(27)25-14-16-5-3-9-23-12-16/h2-12H,13-14H2,1H3,(H,24,26)(H,25,27)
SMILES Code: O=C(C1=CC=C(OC)C(C(NCC2=CC=CN=C2)=O)=C1)NCC3=CC=CN=C3
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >3 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info:
| Biological target: | |
| In vitro activity: | |
| In vivo activity: |
The following data is based on the product molecular weight 376.42 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
| Formulation protocol: | |
| In vitro protocol: | |
| In vivo protocol: |
1: Celestini A, Violi F. A review of picotamide in the reduction of cardiovascular events in diabetic patients. Vasc Health Risk Manag. 2007;3(1):93-8. PMID: 17583179; PMCID: PMC1994050.
2: Hennenberg M, Tamalunas A, Wang Y, Keller P, Schott M, Strittmatter F, Herlemann A, Yu Q, Rutz B, Ciotkowska A, Stief CG, Gratzke C. Inhibition of agonist-induced smooth muscle contraction by picotamide in the male human lower urinary tract outflow region. Eur J Pharmacol. 2017 May 15;803:39-47. doi: 10.1016/j.ejphar.2017.03.022. Epub 2017 Mar 14. PMID: 28315343.
3: Hennenberg M, Miljak M, Herrmann D, Strittmatter F, Walther S, Rutz B, Hocaoglu Y, Kunit T, Schreiber A, Andersson KE, Stief CG, Gratzke C. The receptor antagonist picotamide inhibits adrenergic and thromboxane-induced contraction of hyperplastic human prostate smooth muscle. Am J Physiol Renal Physiol. 2013 Nov 15;305(10):F1383-90. doi: 10.1152/ajprenal.00380.2013. Epub 2013 Sep 18. PMID: 24049147.
4: Allais G, D'Andrea G, Airola G, De Lorenzo C, Mana O, Benedetto C. Picotamide in migraine aura prevention: a pilot study. Neurol Sci. 2004 Oct;25 Suppl 3:S267-9. doi: 10.1007/s10072-004-0304-6. PMID: 15549555.
5: Neri Serneri GG, Coccheri S, Marubini E, Violi F; Drug Evaluation in Atherosclerotic Vascular Disease in Diabetics (DAVID) Study Group. Picotamide, a combined inhibitor of thromboxane A2 synthase and receptor, reduces 2-year mortality in diabetics with peripheral arterial disease: the DAVID study. Eur Heart J. 2004 Oct;25(20):1845-52. doi: 10.1016/j.ehj.2004.07.013. PMID: 15474700.
6: Pogliani E, Milani M. Safety and efficacy of picotamide, a dual anti- thromboxane agent, in patients with thrombocytosis and a previous thromboembolic event: a 1-year observational study. J Int Med Res. 1996 May-Jun;24(3):311-5. doi: 10.1177/030006059602400312. PMID: 8725994.
7: Balsano F, Violi F. Effect of picotamide on the clinical progression of peripheral vascular disease. A double-blind placebo-controlled study. The ADEP Group. Circulation. 1993 May;87(5):1563-9. doi: 10.1161/01.cir.87.5.1563. PMID: 8491012.
8: Pulcinelli FM, Pignatelli P, Pesciotti M, Sebastiani S, Parisi S, Gazzaniga PP. Mechanism of the persisting TxA2 receptor antagonism by picotamide. Thromb Res. 1997 Feb 1;85(3):207-15. doi: 10.1016/s0049-3848(97)00005-4. PMID: 9058495.
9: Violi F, Ghiselli A, Iuliano L, Praticò D, Alessandri C, Balsano F. Inhibition by picotamide of thromboxane production in vitro and ex vivo. Eur J Clin Pharmacol. 1988;33(6):599-602. doi: 10.1007/BF00542494. PMID: 3366163.
10: Ratti S, Quarato P, Casagrande C, Fumagalli R, Corsini A. Picotamide, an antithromboxane agent, inhibits the migration and proliferation of arterial myocytes. Eur J Pharmacol. 1998 Aug 14;355(1):77-83. doi: 10.1016/s0014-2999(98)00467-1. PMID: 9754941.
11: Giustina A, Bossoni S, Cimino A, Comini MT, Gazzoli N, Leproux GB, Wehrenberg WB, Romanelli G, Giustina G. Picotamide, a dual TXB synthetase inhibitor and TXB receptor antagonist, reduces exercise-induced albuminuria in microalbuminuric patients with NIDDM. Diabetes. 1993 Jan;42(1):178-82. doi: 10.2337/diab.42.1.178. PMID: 8420815.
12: Sharma AN, Deyell JS, Sharma SN, Barseghian A. Role of and Recent Evidence for Antiplatelet Therapy in Prevention of Cardiovascular Disease in Diabetes. Curr Cardiol Rep. 2019 Jun 28;21(8):78. doi: 10.1007/s11886-019-1168-y. PMID: 31254105.
13: Gresele P, Corona C, Alberti P, Nenci GG. Picotamide protects mice from death in a pulmonary embolism model by a mechanism independent from thromboxane suppression. Thromb Haemost. 1990 Aug 13;64(1):80-6. PMID: 2274931.
14: Vezza R, Spina D, Tallarida RJ, Nathan M, Page CP, Gresele P. Antivasoconstrictor and antiaggregatory activities of picotamide unrelated to thromboxane A2 antagonism. Thromb Haemost. 1997 Nov;78(5):1385-91. PMID: 9408024.
15: Pibiri L, Petruzzo P, De Giudici A, Brotzu G. Picotamide: prevenzione e terapia della vasculopatia diabetica. Esperienza clinica in doppio cieco [Picotamide: prevention and therapy of diabetic vasculopathies. A double-blind clinical study]. Clin Ter. 1990 May 31;133(4):233-7. Italian. PMID: 2142911.
16: Liu XJ. Design, Synthesis and Evaluation of Antiplatelet Aggregation Inhibitory Activities of the Analogs of Picotamide. Cardiovasc Hematol Agents Med Chem. 2015 Sep 11. Epub ahead of print. PMID: 26362278.
17: Collins CE, Benson MJ, Burnham WR, Rampton DS. Picotamide inhibition of excess in vitro thromboxane B2 release by colorectal mucosa in inflammatory bowel disease. Aliment Pharmacol Ther. 1996 Jun;10(3):315-20. doi: 10.1111/j.0953-0673.1996.00315.x. PMID: 8791957.
18: Cattaneo M, Tenconi PM, Lecchi A, Mannucci PM. In vitro effects of picotamide on human platelet aggregation, the release reaction and thromboxane B2 production. Thromb Res. 1991 Jun 15;62(6):717-24. doi: 10.1016/0049-3848(91)90375-7. PMID: 1926062.
19: D'Andrea G, Perini F, Hasselmark L, Alecci M, Cananzi AR. Effect of picotamide and aspirin, combined or alone, on platelet aggregation in patients with cerebral infarction. Funct Neurol. 1995 Mar-Apr;10(2):91-8. PMID: 7557557.
20: Cocozza M, Milani M, Picano T, Oliviero U, Russo N, Coto V. Antiaggregatory effects of picotamide in long-term treatment: a 2-year, double-blind placebo- controlled trial. Vasc Med. 1997 Nov;2(4):292-5. doi: 10.1177/1358863X9700200403. PMID: 9575601.
